Traders should monitor upcoming 2026 clinical readouts (e.g., pumitamig, gotistobart, trastuzumab pamirtecan) as key value drivers, but anticipate continued revenue contraction and losses in the near term. The management transition adds execution risk; any delays in oncology pipeline milestones could pressure the stock further.
BNTX drugs
BNTX drug pipeline →How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 10 $83.89entry
- T+1 · 8mo ago +8.28%α +8.39% · $90.84
- T+5 · 8mo ago +13.08%α +13.98% · $94.86
- T+20 · 7mo ago +9.76%α +9.92% · $92.08
- T+60 · 6mo ago +5.44%α −6.25% · $88.45
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
BioNTech reported full-year 2025 revenues of €2.87 billion, up 4.3% YoY, but posted a net loss of €1.14 billion (€4.70 diluted loss per share), widening from a €665.3 million loss in 2024. The quarterly revenue declined 23.7% due to lower COVID-19 vaccine demand, and the company issued 2026 revenue guidance of €2.0–2.3 billion, signaling a further decline. Despite a strong cash position of €17.2 billion, the outlook reflects continued transition from pandemic-era revenues to oncology-focused R&D, with multiple late-stage readouts expected in 2026.
Key Financial Metrics
Key Facts
- Full-year 2025 revenue: €2.87 billion (up 4.3% YoY), driven by BMS collaboration revenue in Q3
- Q4 2025 revenue: €907.4 million, down 23.7% YoY due to lower COVID-19 vaccine demand
- Full-year 2025 net loss: €1.14 billion, compared to €665.3 million loss in 2024
- 2026 revenue guidance: €2.0–2.3 billion, implying 19.7%–20.8% YoY decline at midpoint
- Co-founders Ugur Sahin and Özlem Türeci to leave by end of 2026 to lead a new independent mRNA company
- Cash, cash equivalents, and security investments: €17.2 billion as of Dec 31, 2025
Financial Impact
Revenue expected to decline by ~20% in 2026; adjusted R&D expenses to increase to €2.2–2.5 billion despite falling topline
Risk Factors
- Declining revenue and widening losses despite cost discipline
- Management transition risk with co-founders departing by 2026
- Heavy reliance on upcoming clinical data readouts for valuation support
- 2026 guidance implies continued erosion of core vaccine business without near-term commercial offsets
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3252585 |
Track record
38 reports on BNTX
5 of 7 bullish or bearish reports moved the stock their way by T+60. Best: +25.10% at T+20 after the Mar 24, 2026 report. 11 of 15 went positive at some point.
Filters
- Nov 10, 20266d ago 6-K Neutral 4/10 Entry $87.21 Now $85.26 −2.24% settles Feb 8
- Nov 3, 202613d ago 6-K Neutral 5/10 No price data
- Nov 3, 202613d ago 6-K Neutral 5/10 No price data
- Nov 3, 202613d ago Press Release Neutral 5/10 Entry $86.92 Now $85.26 −1.91% settles Feb 1
- Oct 29, 202618d ago Institutional Cluster Mixed 3/10 Entry $89.13 Now $85.26 −4.34% settles Jan 27
- Oct 26, 202621d ago 6-K Bullish 5/10 Entry $86.86 Now $85.26 −1.84% settles Jan 22
- Oct 26, 202621d ago 6-K Bearish 5/10 Entry $86.86 Now $85.26 +1.84% settles Jan 22
- Oct 26, 202621d ago Press Release Bearish 6/10 Entry $86.86 Now $85.26 +1.84% settles Jan 22
- Oct 25, 202622d ago Press Release Bullish 6/10 Entry $86.86 Now $85.26 −1.84% settles Jan 22
- Oct 22, 202625d ago 6-K Neutral 5/10 Entry $89.67 Now $85.26 −4.92% settles Jan 20
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers